LUCA PAUSELLI: Open Payments
NPI 1811457591 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$897 in 63 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $247 · 2025 $897
Food & beverage: $897
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $337 |
| Gilead Sciences, Inc. | 1 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Alkermes, Inc. | 4 | $67 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Supernus Pharmaceuticals, Inc. | 3 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
Products named: VRAYLAR, Yeztugo, REXULTI, ARISTADA, INGREZZA, COBENFY, Qelbree, CAPLYTA.
Industry payments across NY — which companies pay providers there.
